cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.g5mcm9
title: Occurrence Download

description: A dataset containing 3668 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United Kingdom of Great Britain and Northern Ireland",
 "Geometry POLYGON((-1.08181 54.95204,-3.01411 54.96663,-3.69485 54.73903,-3.70058 54.24508,-3.37005 53.93192,-3.37005 53.4653,-2.83613 53.14626,-2.22593 52.08113,-3.12241 51.36177,-4.77627 51.23126,-6.35613 50.00828,-4.87886 49.79118,-0.93572 50.34115,1.50137 50.85678,2.34648 52.50429,-1.08181 54.95204))",
 "TaxonKey is Halichoerus grypus",
 "Year 2015-2025"
 ]
}

 The dataset includes 3668 records from 26 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0047085-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.27980367
title: Validation of salivary proteomic biomarkers for early detection of oral cancer in the Egyptian population

description: The present study evaluated the sensitivity and specificity of important proteomic salivary biomarkers; IL-6, IL-8, and sCD44 in the early detection of oral cancer, and any possible associations with risk factors of oral cancer in an Egyptian population. The present investigation was conducted on 100 individuals; 25 healthy controls, 25 patients having oral potentially malignant disorders (OPMDs) with dysplasia; 25 patients having OPMDs without dysplasia, and 25 oral cancer patients. Demographic data modified gingival index, oral hygiene level, and salivary levels of the biomarkers were assessed. Salivary levels of IL-6, IL-8, and sCD44 progressively increased with increased disease severity. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer, sCD44 levels had a discriminating power between normal and dysplastic tissues with high sensitivity and specificity. A positive correlation was found between the three biomarkers and the grade of oral squamous cell carcinoma (OSCC) and with different risk factors. This is the first study that evaluated multiple salivary proteomic biomarkers in the Egyptian population, and the results validate the ability of IL-6, IL-8, and sCD44 to be used as sensitive diagnostic and prognostic biomarkers for screening and early detection of oral cancer. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer.sCD44 levels have a discriminating power between normal and dysplastic tissues with high sensitivity and specificity.There is a positive correlation between the three biomarkers and different oral cancer risk factors.Assessment of salivary levels of these proteomic biomarkers constitutes a simple, noninvasive, point-of-care diagnostic tool.Salivary proteomic biomarkers may help identify individuals at high risk for oral cancer, facilitate early detection of oral cancer and malignant transformation in OPMDs. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer. sCD44 levels have a discriminating power between normal and dysplastic tissues with high sensitivity and specificity. There is a positive correlation between the three biomarkers and different oral cancer risk factors. Assessment of salivary levels of these proteomic biomarkers constitutes a simple, noninvasive, point-of-care diagnostic tool. Salivary proteomic biomarkers may help identify individuals at high risk for oral cancer, facilitate early detection of oral cancer and malignant transformation in OPMDs.
DOI: 10.6084/m9.figshare.27980367.v1
title: Validation of salivary proteomic biomarkers for early detection of oral cancer in the Egyptian population

description: The present study evaluated the sensitivity and specificity of important proteomic salivary biomarkers; IL-6, IL-8, and sCD44 in the early detection of oral cancer, and any possible associations with risk factors of oral cancer in an Egyptian population. The present investigation was conducted on 100 individuals; 25 healthy controls, 25 patients having oral potentially malignant disorders (OPMDs) with dysplasia; 25 patients having OPMDs without dysplasia, and 25 oral cancer patients. Demographic data modified gingival index, oral hygiene level, and salivary levels of the biomarkers were assessed. Salivary levels of IL-6, IL-8, and sCD44 progressively increased with increased disease severity. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer, sCD44 levels had a discriminating power between normal and dysplastic tissues with high sensitivity and specificity. A positive correlation was found between the three biomarkers and the grade of oral squamous cell carcinoma (OSCC) and with different risk factors. This is the first study that evaluated multiple salivary proteomic biomarkers in the Egyptian population, and the results validate the ability of IL-6, IL-8, and sCD44 to be used as sensitive diagnostic and prognostic biomarkers for screening and early detection of oral cancer. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer.sCD44 levels have a discriminating power between normal and dysplastic tissues with high sensitivity and specificity.There is a positive correlation between the three biomarkers and different oral cancer risk factors.Assessment of salivary levels of these proteomic biomarkers constitutes a simple, noninvasive, point-of-care diagnostic tool.Salivary proteomic biomarkers may help identify individuals at high risk for oral cancer, facilitate early detection of oral cancer and malignant transformation in OPMDs. Salivary IL-8 and IL-6 levels possess a discriminating potential from normal tissue through different degrees of dysplasia to oral cancer. sCD44 levels have a discriminating power between normal and dysplastic tissues with high sensitivity and specificity. There is a positive correlation between the three biomarkers and different oral cancer risk factors. Assessment of salivary levels of these proteomic biomarkers constitutes a simple, noninvasive, point-of-care diagnostic tool. Salivary proteomic biomarkers may help identify individuals at high risk for oral cancer, facilitate early detection of oral cancer and malignant transformation in OPMDs.
DOI: 10.17026/ar/spnlzd
title: PAN-00180894 - deck

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00180894&lt;/p&gt;
description: Modified: 2025-11-11T12:49:13+01:00
DOI: 10.57715/unr/1fa2mb/u2u2qz
title: 2014_Cualidades Docentes Memorables.ods

description: Registro de 2014 sobre docentes memorables.
DOI: 10.57715/unr/1fa2mb/8ffe5h
title: 2019_Cualidades Docentes Memorables.ods

description: Archivo de 2019.
DOI: 10.57715/unr/1fa2mb/lvnqab
title: 2010_Cualidades Docentes Memorables.ods

description: Relevamiento de 2010 sobre docentes memorables.
DOI: 10.57715/unr/1fa2mb/ltxp2q
title: 2003_Cualidades Docentes Memorables.ods

description: Registro de las cualidades de docentes memorables identificadas por ingresantes en 2003; mismas variables.
DOI: 10.15468/dl.9gau6a
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((103.014 -1.454819, 102.943714 -1.460385, 102.875158 -1.476945, 102.810019 -1.504093, 102.749899 -1.541159, 102.696278 -1.587232, 102.650477 -1.641178, 102.613623 -1.701669, 102.586624 -1.767217, 102.570146 -1.836207, 102.564595 -1.906941, 102.57011 -1.977678, 102.586555 -2.046676, 102.613528 -2.112237, 102.650365 -2.172744, 102.696161 -2.226708, 102.749787 -2.272799, 102.809924 -2.309881, 102.875089 -2.337041, 102.943678 -2.35361, 103.014 -2.359178, 103.084322 -2.35361, 103.152911 -2.337041, 103.218076 -2.309881, 103.278213 -2.272799, 103.331839 -2.226708, 103.377635 -2.172744, 103.414472 -2.112237, 103.441445 -2.046676, 103.45789 -1.977678, 103.463405 -1.906941, 103.457854 -1.836207, 103.441376 -1.767217, 103.414377 -1.701669, 103.377523 -1.641178, 103.331722 -1.587232, 103.278101 -1.541159, 103.217981 -1.504093, 103.152842 -1.476945, 103.084286 -1.460385, 103.014 -1.454819))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0047086-251120083545085/datasets/export for details.
DOI: 10.57715/unr/1fa2mb/bfx8sf
title: 2006_Cualidades Docentes Memorables.ods

description: Compilación de 2006 con información sobre docentes memorables.
DOI: 10.57715/unr/1fa2mb/a5nig6
title: 2016_Cualidades Docentes Memorables.ods

description: Archivo de 2016 con datos recolectados sobre docentes memorables.
DOI: 10.6084/m9.figshare.29940934
title: Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis

description: This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis. English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included. The main evaluation indicators included progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and severe adverse events (SAEs). Ten studies were included in the analysis. The results indicated that in the dMMR population, ICIs provide superior survival benefits. Among these, Dostarlimab combined with carboplatin and paclitaxel (CP) had the highest PFS and OS rates. For the pMMR population, Selinexor + CP offers significant benefits over CP alone, although OS outcome data are limited. In pMMR patients with prior chemotherapy, the lenvatinib + pembrolizumab strategy may provide additional PFS benefits relative to chemotherapy treatment. ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise. Network meta-analysis assessed immune and targeted therapies for advanced/recurrent endometrial cancer patients with dMMR and pMMR statuses. ICIs showed superior survival benefits in dMMR patients, with Dostarlimab + carboplatin and paclitaxel (CP) offering highest PFS and OS rates. Selinexor + CP provided significant benefits for pMMR patients compared with CP alone, although OS data are limited. Lenvatinib + pembrolizumab may offer PFS advantages for pMMR patients with prior chemotherapy. Research suggests that ICIs + chemotherapy benefits patients with dMMR; selinexor + chemotherapy may aid in the development of pMMR.
DOI: 10.6084/m9.figshare.29940934.v1
title: Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis

description: This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis. English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included. The main evaluation indicators included progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), and severe adverse events (SAEs). Ten studies were included in the analysis. The results indicated that in the dMMR population, ICIs provide superior survival benefits. Among these, Dostarlimab combined with carboplatin and paclitaxel (CP) had the highest PFS and OS rates. For the pMMR population, Selinexor + CP offers significant benefits over CP alone, although OS outcome data are limited. In pMMR patients with prior chemotherapy, the lenvatinib + pembrolizumab strategy may provide additional PFS benefits relative to chemotherapy treatment. ICIs offered advantages for the dMMR population, whereas selinexor could provide survival benefits for the pMMR population. For pMMR patients who have received prior chemotherapy, the lenvatinib plus pembrolizumab strategy shows promise. Network meta-analysis assessed immune and targeted therapies for advanced/recurrent endometrial cancer patients with dMMR and pMMR statuses. ICIs showed superior survival benefits in dMMR patients, with Dostarlimab + carboplatin and paclitaxel (CP) offering highest PFS and OS rates. Selinexor + CP provided significant benefits for pMMR patients compared with CP alone, although OS data are limited. Lenvatinib + pembrolizumab may offer PFS advantages for pMMR patients with prior chemotherapy. Research suggests that ICIs + chemotherapy benefits patients with dMMR; selinexor + chemotherapy may aid in the development of pMMR.
DOI: 10.5281/zenodo.17899441
title: INKLYUZIV TA'LIM JARAYONIDA IJTIMOIY ISH VA PSIXOLOGIK XIZMATNING O'RNI
DOI: 10.6084/m9.figshare.28689444
title: Hesperidin alleviates pulmonary fibrosis by regulating EI24-mediated autophagy

description: Etoposide-induced protein 2.4 (EI24), an essential component of autophagy, is lowly expressed in pulmonary fibrosis. Hesperidin (Hes), a flavonoid, can regulate autophagy in various diseases. However, whether Hes can inhibit pulmonary fibrosis by mechanically regulating EI24-mediated autophagy has not been uncovered. RLE-6TN cells were treated with transforming growth factor β1 (TGF-β1) and rats were injected with bleomycin (BLM) to construct the pulmonary fibrosis model. The effect of Hes on pulmonary fibrosis was evaluated by cell counting kit-8, immunofluorescence, hematoxylin and eosin, masson trichome staining and western blotting. Hes reduced cell viability of TGF-β1-induced RLE-6TN cells. Administration of Hes restored the decrease in autophagy marker levels in TGF-β1-induced RLE-6TN cells. Hes inhibited the transcriptional and translational levels of α-SMA, collagen I and fibronectin that were increased by TGF-β1 in RLE-6TN cells. Mechanically, Hes restored EI24 expression, and EI24 knockdown reversed the effect of Hes on the expressions of autophagy and fibrosis-related proteins. Additionally, Hes enhanced autophagy and fibrosis markers, which were worsened by EI24 knockdown in BLM-induced rats. Hes activated autophagy by upregulating EI24, which improved pulmonary fibrosis both <i>in vitro</i> and <i>in vivo</i>. Hes activated TGF-β1-induced autophagy in RLE-6TN cells.Hes inhibited TGF-β1-induced fibrosis in RLE-6TN cells.Hes suppressed fibrosis by regulating EI24-mediated autophagy in TGF-β1-induced RLE-6TN cells.Hes attenuated BLM-induced fibrosis of rat lung tissue.Hes activated autophagy in BLM-induced fibrosis <i>in vivo.</i> Hes activated TGF-β1-induced autophagy in RLE-6TN cells. Hes inhibited TGF-β1-induced fibrosis in RLE-6TN cells. Hes suppressed fibrosis by regulating EI24-mediated autophagy in TGF-β1-induced RLE-6TN cells. Hes attenuated BLM-induced fibrosis of rat lung tissue. Hes activated autophagy in BLM-induced fibrosis <i>in vivo.</i> In this study, we looked at how a natural compound called Hesperidin might help fight a common type of lung disease called pulmonary fibrosis. This disease can harm lung tissue structures and may cause death. We treated rats with a substance that causes pulmonary fibrosis, then gave some of them Hesperidin to see if it would help. We watched how their weight changed, how much the lung structure damaged and how many lung fibroses they had. Our results were promising: the rats treated with Hesperidin were healthier than those that weren’t. They had less lung weight, had more normal lung tissue structure, and showed fewer signs of fibrosis. This suggests that Hesperidin could be a new way to protect against pulmonary fibrosis.
DOI: 10.6084/m9.figshare.28689444.v1
title: Hesperidin alleviates pulmonary fibrosis by regulating EI24-mediated autophagy

description: Etoposide-induced protein 2.4 (EI24), an essential component of autophagy, is lowly expressed in pulmonary fibrosis. Hesperidin (Hes), a flavonoid, can regulate autophagy in various diseases. However, whether Hes can inhibit pulmonary fibrosis by mechanically regulating EI24-mediated autophagy has not been uncovered. RLE-6TN cells were treated with transforming growth factor β1 (TGF-β1) and rats were injected with bleomycin (BLM) to construct the pulmonary fibrosis model. The effect of Hes on pulmonary fibrosis was evaluated by cell counting kit-8, immunofluorescence, hematoxylin and eosin, masson trichome staining and western blotting. Hes reduced cell viability of TGF-β1-induced RLE-6TN cells. Administration of Hes restored the decrease in autophagy marker levels in TGF-β1-induced RLE-6TN cells. Hes inhibited the transcriptional and translational levels of α-SMA, collagen I and fibronectin that were increased by TGF-β1 in RLE-6TN cells. Mechanically, Hes restored EI24 expression, and EI24 knockdown reversed the effect of Hes on the expressions of autophagy and fibrosis-related proteins. Additionally, Hes enhanced autophagy and fibrosis markers, which were worsened by EI24 knockdown in BLM-induced rats. Hes activated autophagy by upregulating EI24, which improved pulmonary fibrosis both <i>in vitro</i> and <i>in vivo</i>. Hes activated TGF-β1-induced autophagy in RLE-6TN cells.Hes inhibited TGF-β1-induced fibrosis in RLE-6TN cells.Hes suppressed fibrosis by regulating EI24-mediated autophagy in TGF-β1-induced RLE-6TN cells.Hes attenuated BLM-induced fibrosis of rat lung tissue.Hes activated autophagy in BLM-induced fibrosis <i>in vivo.</i> Hes activated TGF-β1-induced autophagy in RLE-6TN cells. Hes inhibited TGF-β1-induced fibrosis in RLE-6TN cells. Hes suppressed fibrosis by regulating EI24-mediated autophagy in TGF-β1-induced RLE-6TN cells. Hes attenuated BLM-induced fibrosis of rat lung tissue. Hes activated autophagy in BLM-induced fibrosis <i>in vivo.</i> In this study, we looked at how a natural compound called Hesperidin might help fight a common type of lung disease called pulmonary fibrosis. This disease can harm lung tissue structures and may cause death. We treated rats with a substance that causes pulmonary fibrosis, then gave some of them Hesperidin to see if it would help. We watched how their weight changed, how much the lung structure damaged and how many lung fibroses they had. Our results were promising: the rats treated with Hesperidin were healthier than those that weren’t. They had less lung weight, had more normal lung tissue structure, and showed fewer signs of fibrosis. This suggests that Hesperidin could be a new way to protect against pulmonary fibrosis.
DOI: 10.5281/zenodo.17899440
title: INKLYUZIV TA'LIM JARAYONIDA IJTIMOIY ISH VA PSIXOLOGIK XIZMATNING O'RNI
DOI: 10.57715/unr/1fa2mb/yw80po
title: 2013_Cualidades Docentes Memorables.ods

description: rchivo de 2013 con datos sobre docentes memorables.
DOI: 10.6084/m9.figshare.30152916
title: Web-based predictive tool for vaginal and vulvar melanomas: a machine learning study

description: One in every 41 women develops malignant melanoma in their lifetime, with noncutaneous melanomas arising in areas such as the genitourinary (GU) system being particularly rare and aggressive. We used machine learning (ML) to build prognostic models for vaginal (VaM) and vulvar (VuM) melanomas and developed the first predictive web-based tool for survival in these cancers. We leveraged the SEER database (2000–2020) to assemble our cohort and extract relevant clinical and demographic variables. Prognostic factors were screened using univariate and multivariate Cox proportional hazards regression analyses. Subsequently, we developed five machine-learning classifiers to predict 5-year survival. The discrimination of each model was assessed using the area under the receiver operating characteristic curve (AUC-ROC), and calibration was examined to ensure reliability. Kaplan–Meier analyses were performed to visualize survival distributions across key subgroups. This study included 1575 patients, of whom 372 and 1203 had VaM and VuM, respectively. The median patient age was 67 years, and the median tumor size was 2.4 cm. The 5-year survival rate of patients with VuM (45.4%) was significantly higher than that of patients with VaM (15.2%) (P &lt; 0.001). This study highlights the aggressive nature of rare GU melanomas and the importance of surgical intervention and caution in the use of chemotherapy and radiotherapy. This study focused on rare and aggressive cancers known as VaM and VuM melanomas, which arise in the GU system. Using machine learning techniques, we analyzed patient data to identify factors affecting survival and created the first web-based tool to predict survival outcomes in these cancers. This study found that surgical treatment significantly improved survival rates, whereas chemotherapy and radiotherapy had mixed effects. Tumor size and marital status were identified as important predictors of survival. The developed web tool allows clinicians to input patient information and receive personalized survival predictions, helping guide treatment decisions. This study highlights the need for cautious use of therapies and offers innovative ways to personalize care for patients with these rare cancers of therapies and offers innovative ways to personalize care for patients with these rare cancers.